share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  12/21 06:05

Moomoo AI 已提取核心訊息

MIRA Pharmaceuticals reported on December 20, 2024, that Cherry Bekaert LLP resigned as its independent registered public accounting firm on December 16. Cherry Bekaert's reports for 2022 and 2023 contained no adverse opinions, but noted material weaknesses in internal control over financial reporting. No disagreements or reportable events occurred during their tenure, except for the noted material weaknesses.On December 18, 2024, MIRA engaged Salberg & Company P.A. as its new independent auditor for the fiscal year ending December 31, 2024. This decision was recommended by the Audit Committee and approved by the Board of Directors. MIRA confirmed no prior consultations with Salberg regarding accounting principles, audit opinions, or any matters of disagreement or reportable events.
MIRA Pharmaceuticals reported on December 20, 2024, that Cherry Bekaert LLP resigned as its independent registered public accounting firm on December 16. Cherry Bekaert's reports for 2022 and 2023 contained no adverse opinions, but noted material weaknesses in internal control over financial reporting. No disagreements or reportable events occurred during their tenure, except for the noted material weaknesses.On December 18, 2024, MIRA engaged Salberg & Company P.A. as its new independent auditor for the fiscal year ending December 31, 2024. This decision was recommended by the Audit Committee and approved by the Board of Directors. MIRA confirmed no prior consultations with Salberg regarding accounting principles, audit opinions, or any matters of disagreement or reportable events.
MIRA製藥公司於2024年12月20日報告稱,Cherry Bekaert LLP於12月16日辭去了其獨立註冊公共會計師事務所。Cherry Bekaert在2022年和2023年的報告中沒有不利意見,但指出財務報告內部控制的重大缺陷。 在他們的任期內沒有發生任何分歧或可報告事件,除了所提到的重大缺陷。2024年12月18日,MIRA聘請Salberg & Company P.A.作爲其截至2024年12月31日財政年度的新獨立核數師。此決定由審計委員會推薦,並得到了董事會的批准。MIRA確認未與Salberg就會計原則、審計意見或任何分歧或可報告事件進行過事前諮詢。
MIRA製藥公司於2024年12月20日報告稱,Cherry Bekaert LLP於12月16日辭去了其獨立註冊公共會計師事務所。Cherry Bekaert在2022年和2023年的報告中沒有不利意見,但指出財務報告內部控制的重大缺陷。 在他們的任期內沒有發生任何分歧或可報告事件,除了所提到的重大缺陷。2024年12月18日,MIRA聘請Salberg & Company P.A.作爲其截至2024年12月31日財政年度的新獨立核數師。此決定由審計委員會推薦,並得到了董事會的批准。MIRA確認未與Salberg就會計原則、審計意見或任何分歧或可報告事件進行過事前諮詢。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息